E. Goldbach

发表

A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.

E. Merisko-Liversidge, G. Liversidge, G. Tonn, 2012, Journal of pharmaceutical sciences.

Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.

R. Motter, M. Adler, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

A series of C-Terminal amino alcohol dipeptide Aβ inhibitors

E. Thorsett, L. Latimer, J. Audia, 2002 .

Triazolopyridazine LRRK2 kinase inhibitors.

M. Adler, H. Sham, M. Franzini, 2013, Bioorganic & medicinal chemistry letters.

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

R. Neitz, M. Adler, H. Sham, 2013, Bioorganic & medicinal chemistry letters.

α4β1Integrin-dependent Cell Adhesion Is Regulated by a Low Affinity Receptor Pool That Is Conformationally Responsive to Ligand (*)

C. Vandevert, T. Yednock, L. Fritz, 1995, The Journal of Biological Chemistry.

Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.

M. Bergeron, G. Tonn, A. Olaharski, 2013, Toxicology and applied pharmacology.

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration.

G. Tóth, H. Sham, N. Yao, 2011, Bioorganic & medicinal chemistry letters.

Alpha 4 beta 1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand.

C. Vandevert, T. Yednock, L. Fritz, 1995, The Journal of biological chemistry.

Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors.

H. Sham, T. Yednock, M. Bova, 2009, Bioorganic & medicinal chemistry letters.

Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.

R. Motter, D. Kholodenko, H. Sham, 2010, Bioorganic & medicinal chemistry letters.

Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

F. D. Miller, R. Motter, D. Kholodenko, 2000, Journal of neurochemistry.

Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease

R. Motter, D. Kholodenko, R. Barbour, 2010, Alzheimer's Research & Therapy.

Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures

Richard M. Page, T Bonhoeffer, T. Bonhoeffer, 2013, Molecular Psychiatry.

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.

Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.

H. Sham, L. Latimer, M. Bova, 2013, Bioorganic & medicinal chemistry letters.

Effects of single and multiple dose oral administration of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain and CSF of cynomolgus monkeys

R. Motter, D. Kholodenko, J. Sauer, 2010, Alzheimer's & Dementia.

Discovery of sulfonamide-pyrazole gamma-secretase inhibitors.

H. Sham, J. Sauer, P. Keim, 2010, Bioorganic & medicinal chemistry letters.

APP-selective gamma secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid beta in the PDAPP mouse model of Alzheimer's disease

R. Motter, D. Kholodenko, K. Khan, 2010, Alzheimer's & Dementia.

Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration

R. Motter, D. Kholodenko, K. Hu, 2010, Alzheimer's & Dementia.

Discovery of a novel sulfonamide-pyrazolopiperidine series as potent and efficacious gamma-secretase inhibitors.

H. Sham, M. Bova, J. Sauer, 2010, Bioorganic & medicinal chemistry letters.

Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors.

H. Sham, M. Bova, J. Sauer, 2011, Bioorganic & Medicinal Chemistry Letters.

Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's disease.

M. Bova, J. Sauer, G. Basi, 2011, Bioorganic & medicinal chemistry letters.

Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies

K. Quinn, R. Gullapalli, E. Goldbach, 2012, Drug delivery.

N-Bridged bicyclic sulfonamides as inhibitors of gamma-secretase.

H. Sham, M. Bova, J. Sauer, 2009, Bioorganic & medicinal chemistry letters.

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

M. Adler, H. Sham, M. Franzini, 2013, Bioorganic & medicinal chemistry letters.